R
Retension Pharmaceuticals
Innovative hypertension treatments reducing cardiovascular risks with novel, well-tolerated therapies
About Retension Pharmaceuticals
Retension Pharmaceuticals focuses on developing innovative treatments for hypertension, targeting patients whose blood pressure remains uncontrolled despite existing medications. Operating in the life sciences sector, the company aims to address the high unmet need for effective and well-tolerated therapies to reduce cardiovascular risks. Retension Pharmaceuticals plans to conduct a multi-center, double-blind, placebo-controlled Phase 2 trial to further evaluate their lead candidate, RTN 001. This trial will assess the drug's impact on blood pressure, confirm its pharmacokinetic and pharmacodynamic profile, and expand on its safety profile. The company primarily serves patients with uncontrolled hypertension and collaborates with healthcare providers and research institutions. Retension Pharmaceuticals generates revenue through the development and potential commercialization of its therapeutic assets. The business model includes conducting clinical trials, securing regulatory approvals, and partnering with pharmaceutical companies for distribution and marketing.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Falls Church, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 77.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2025 | $15M | $60M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Aug 2024 | $10M | $42M | Collage Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Retension Pharmaceuticals is 540 monthly website visits, down 61.4% over the last three months. Retension Pharmaceuticals's team grew 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Collage Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Retension Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Retension Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.